11月8日,生物制药企业Rhythm Pharmaceuticals Inc. (RYTM.US)股价盘中大涨5.7%,报收67.10美元/股。该股近期交投较为活跃,当日换手率为1%,振幅达6.48%。
Rhythm Pharmaceuticals最新财报显示,公司实现营收3325万美元,净亏损4364万美元,每股亏损0.73美元,毛利率为88%。尽管亏损持续,但分析师普遍看好公司在遗传性肥胖症领域的潜力。
公司主打产品Setmelanotide是治疗遗传性肥胖症的一种黑素皮质素4受体激动剂。这一罕见病缺乏有效治疗方案,Setmelanotide可望成为突破性疗法。在11家分析师中,有10家给予买入评级,预计产品上市后将带动营收增长。
Rhythm Pharmaceuticals是一家专注于罕见疾病的生物制药公司,其主要收入来源于美国、德国等地。分析人士认为,在全球市场需求的带动下,Rhythm Pharmaceuticals有望持续扩大经营规模。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.